Augustine Therapeutics is excited to announce a significant milestone in its journey toward addressing unmet medical needs. The company, renowned for its pioneering research and commitment to developing innovative therapies, has successfully raised 84,200,000 dollars in its latest funding round. This robust financial backing will empower Augustine Therapeutics to accelerate its ambitious research and development programs aimed at discovering and advancing novel treatments for patients suffering from Charcot-Marie-Tooth disease (CMT) and other peripheral neuropathies, neurodegenerative, and cardiometabolic disorders. Rooted in the ground-breaking scientific contributions from esteemed institutions such as VIB and KU Leuven, Augustine Therapeutics leverages a strong foundation of academic excellence and cutting-edge biomedical research. The funding will not only enhance preclinical and clinical research initiatives but also support the optimization of drug delivery systems and further collaborations with partners who share the vision of transforming patient care. Endorsed by a distinguished cadre of supporters including Asabys Partners, Eli Lilly and Company, V-Bio Ventures, PMV, AdBio Partners, VIB, Gemma Frisius Fund, and the CMT Research Foundation, the company is well-positioned to redefine treatment pathways and improve outcomes for individuals affected by these debilitating conditions. This investment is a testament to the confidence placed in Augustine Therapeutics' scientific strategy and its commitment to delivering tangible benefits to patients, while also reinforcing robust practices in innovation and transparency. As the company embarks on its next phase of growth, it remains dedicated to its mission of transforming therapeutic landscapes and providing hope to patients worldwide.
Augustine Therapeutics Secures $84.2M Series A to Fuel Innovative CMT and Neurological Disorder Therapies
Recently funded · $84.2M Series aBiotechnology
Get the full Augustine Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
